Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Other Accumulated Expenses (2020 - 2025)

Bioventus (BVS) has disclosed Other Accumulated Expenses for 5 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 7.48% year-over-year to $4.2 million, compared with a TTM value of $4.2 million through Dec 2025, up 7.48%, and an annual FY2025 reading of $4.2 million, up 7.48% over the prior year.
  • Other Accumulated Expenses was $4.2 million for Q4 2025 at Bioventus, down from $4.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $10.2 million in Q2 2021 and bottomed at $3.0 million in Q4 2021.
  • Average Other Accumulated Expenses over 5 years is $4.6 million, with a median of $4.1 million recorded in 2024.
  • The sharpest move saw Other Accumulated Expenses surged 33.52% in 2023, then decreased 18.67% in 2024.
  • Year by year, Other Accumulated Expenses stood at $3.6 million in 2021, then grew by 1.38% to $3.6 million in 2022, then skyrocketed by 33.52% to $4.8 million in 2023, then decreased by 18.67% to $3.9 million in 2024, then grew by 7.48% to $4.2 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for BVS at $4.2 million in Q4 2025, $4.4 million in Q2 2025, and $3.9 million in Q4 2024.